Fortune: the fastest growing pharmaceutical company in the world

Source: it's no surprise that on June 24, 2015, Xinkangjie / shaojianguo ranked second and third in the list, which were two large biotechnology companies, considering the rise of biopharmaceuticals But only, and only, one large pharmaceutical company barely made it to the top five So what makes this big pharmaceutical company the top 5? The company is one of the competitors in the 2009 global pharmaceutical super merger and acquisition Super class M & A has increased the company's sales by more than 75% from 2009 to 2011, but this also led to the company's growth of 9% in 2009 to 2014 The company is not Roche, which successfully acquired Pfizer of Wyeth with us $68 billion in 2009, or acquired 44% shares of Genentech with us $46.8 billion in 2009, thus controlling 100% of Genentech The company succeeded in taking over Schering plough's MSD with us $41.1 billion After the completion of the acquisition, its sales revenue increased rapidly Of course, a series of cost reduction efforts after the acquisition are indispensable MSD has been suffering from the challenge of generic drugs due to its allergy and asthma drugs, shunerling (montelukast, Singulair), but the company will make a comeback with the tumor immunotherapy drug keytruda (pembrolizumab) and the new hepatitis C cocktail treatment drugs (grazoprevir, elbasvir) From 2009 to 2014, Elgin ranked fourth in fortune's list of the fastest growing pharmaceutical companies in the world with 10% growth in these five years, mainly due to the Botox (Botox a, Botox) in its R & D pipeline and some other drugs with good sales The sale of Botox is driven by a number of medical uses in addition to approved beauty injection uses Of course, this increase is also the reason why atweis pocketed its revenue with us $66 billion The transaction was completed in March, and the brand was retained Now, the shareholders of atweis have accepted the name of eljian and started business The following companies are among the top three fastest growing pharmaceutical companies on fortune With a growth rate of 17.3% in five years, Baijian Aidi ranked third in the ranking, with a revenue of US $9.7 billion in 2014 In the company's growth, the multiple sclerosis treatment drug dimethyl fumarate (tecfidera) plays an important role, and the drug is expected to continue this trend, with sales expected to reach US $4.1 billion in 2015 The second place in the ranking is Searle gene The growth trend of lenalidomide and Revlimid, the company's blood system tumor drug, will not change, at least there will be no biological similar drugs next year The company's 5-year growth rate is 23.3%, and its revenue reached 7.7 billion US dollars in 2014, which is moving towards the ambitious goal of ceobob hugin of 12 billion US dollars in 2017 Lenalidomide and Revlimid contributed about US $5 billion to the company in 2014, since the drug obtained indications for new diagnosis of multiple myeloma According to evaluatepharma's forecast, the drug will sell for at least $8 billion in 2020 The reason why Gilead science won the top of the list is of course Before the arrival of hepatitis C treatment drugs, Gilead science was already a powerful anti-virus company, and made headlines with its fast listing sofosbuvir, sovaldi and harvoni (ledipasvir, sofibvir compound preparation), which made Gilead science's revenue reach 24.9 billion dollars in 2014 Geely Tech's growth rate is 28.8% in five years Even though the company's growth rate will slow down this year, Geely Tech's sales revenue in 2015 is expected to reach US $29 billion, due to the approval of iberville's hepatitis C drug viekirapak and the discount based on sales revenue.